Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
April 22, 2019
J&J And Colgate Face Latest Talc Trial Together In Calif.
Asbestos hidden for decades in talcum powder products made by Johnson & Johnson and Colgate-Palmolive gave a 61-year-old woman mesothelioma, leaving her only months to live, her attorney told a California jury Monday on the first day of trial.
-
April 22, 2019
Feds Seek Pause Of SEC's Civil Suit Against Theranos Official
The government has urged a California federal court to pause a civil suit against a former Theranos Inc. executive amid related pending criminal proceedings in which the ex-leader of the wannabe bloodwork disruptor faces charges over some of the same conduct.
-
April 22, 2019
J&J Settles Wash. AG's Pelvic Mesh Case Just Before Trial
Johnson & Johnson has agreed to pay $9.9 million to settle the state of Washington’s allegations that its Ethicon subsidiary downplayed the risks of its surgical mesh devices in its marketing, avoiding a Seattle trial that was about to begin Monday.
-
April 22, 2019
Aveo Pharma Stock-Drop Suit Lands In Massachusetts
A proposed class action accusing embattled Aveo Pharmaceuticals Inc., its CEO and two others of misleading investors ahead of a sharp January stock drop was moved to Massachusetts federal court Monday after the company's unopposed bid to transfer the suit from New York.
-
April 22, 2019
Deals Rumor Mill: Dassault, Cerberus, Bain
Dassault Systèmes is looking for stateside acquisitions, Cerberus Capital Management is looking to raise $2.5 billion with a new direct lending-focused fund and Bain Capital is looking at options for technology company Waystar.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals